Haloperidol decanoate (BioDeep_00000858671)

   


代谢物信息卡片


4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidyl decanoate

化学式: C31H41ClFNO3 (529.2758838000001)
中文名称: 氟哌啶醇-d4癸酸酯
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl
InChI: InChI=1S/C31H41ClFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3

描述信息

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist

同义名列表

2 个代谢物同义名

4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidyl decanoate; Haloperidol decanoate



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Raahil Kajani, Austin Apramian, Arturo Vega, Nitin Ubhayakar, Prissilla Xu, Antonio Liu. Neuroleptic malignant syndrome in a COVID-19 patient. Brain, behavior, and immunity. 2020 08; 88(?):28-29. doi: 10.1016/j.bbi.2020.05.042. [PMID: 32425332]
  • Bart G J Dekkers, Ruben J Eck, Jan C Ter Maaten, Daniël J Touw. An acute oral intoxication with haloperidol decanoate. The American journal of emergency medicine. 2017 Sep; 35(9):1387.e1-1387.e2. doi: 10.1016/j.ajem.2017.07.013. [PMID: 28705742]
  • Jordyn M Kippe, Toni M Mueller, Vahram Haroutunian, James H Meador-Woodruff. Abnormal N-acetylglucosaminyltransferase expression in prefrontal cortex in schizophrenia. Schizophrenia research. 2015 Aug; 166(1-3):219-24. doi: 10.1016/j.schres.2015.06.002. [PMID: 26104473]
  • Joseph P McEvoy, Matthew Byerly, Robert M Hamer, Rosalie Dominik, Marvin S Swartz, Robert A Rosenheck, Neepa Ray, J Steven Lamberti, Peter F Buckley, Tania M Wilkins, T Scott Stroup. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014 May; 311(19):1978-87. doi: 10.1001/jama.2014.4310. [PMID: 24846035]
  • Marija Bošković, Iztok Grabnar, Tea Terzič, Blanka Kores Plesničar, Tomaž Vovk. Oxidative stress in schizophrenia patients treated with long-acting haloperidol decanoate. Psychiatry research. 2013 Dec; 210(3):761-8. doi: 10.1016/j.psychres.2013.08.035. [PMID: 24041751]
  • Raquel Cristine Silva Barcelos, Dalila Moter Benvegnú, Nardeli Boufleur, Patrícia Reckziegel, Liz Girardi Müller, Camila Pase, Tatiana Emanuelli, Marilise Escobar Bürger. Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter. Neurotoxicity research. 2010 Apr; 17(3):228-37. doi: 10.1007/s12640-009-9095-0. [PMID: 19644727]
  • Tetsuji Kubakawa, Hideto Niimura. [Psychiatric care for patients with addiction of amphetamine, CNS stimulant]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. 2009; 111(7):850-53. doi: NULL. [PMID: 19999296]
  • Roselei Fachinetto, Jardel G Villarinho, Caroline Wagner, Romaiana P Pereira, Daiana Silva Avila, Marilise E Burger, João Batista Calixto, João B T Rocha, Juliano Ferreira. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. Progress in neuro-psychopharmacology & biological psychiatry. 2007 Oct; 31(7):1478-86. doi: 10.1016/j.pnpbp.2007.06.028. [PMID: 17669571]
  • Joseph P McEvoy. Risks versus benefits of different types of long-acting injectable antipsychotics. The Journal of clinical psychiatry. 2006; 67 Suppl 5(?):15-8. doi: NULL. [PMID: 16822092]
  • C Cristina, G Díaz-Torga, A Baldi, A Góngora, M Rubinstein, M J Low, D Becú-Villalobos. Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology. 2005 Jul; 146(7):2952-62. doi: 10.1210/en.2004-1445. [PMID: 15817666]
  • Takeshi Sassa, Tetsuya Suhara, Hiroo Ikehira, Takayuki Obata, Franck Girard, Shuji Tanada, Yoshiro Okubo. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate. Psychiatry and clinical neurosciences. 2002 Dec; 56(6):637-42. doi: 10.1046/j.1440-1819.2002.01068.x. [PMID: 12485307]
  • O A Andreassen, C Weber, H A Jørgensen. Coenzyme Q10 does not prevent oral dyskinesias induced by long-term haloperidol treatment of rats. Pharmacology, biochemistry, and behavior. 1999 Nov; 64(3):637-42. doi: 10.1016/s0091-3057(99)00118-5. [PMID: 10548281]
  • L Pan, R Vander Stichele, M T Rosseel, J A Berlo, N De Schepper, F M Belpaire. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. Therapeutic drug monitoring. 1999 Oct; 21(5):489-97. doi: 10.1097/00007691-199910000-00001. [PMID: 10519444]
  • L Pan, M T Rosseel, F M Belpaire. Comparison of two high-performance liquid chromatographic methods for monitoring plasma concentrations of haloperidol and reduced haloperidol. Therapeutic drug monitoring. 1998 Apr; 20(2):224-30. doi: 10.1097/00007691-199804000-00015. [PMID: 9558139]
  • E Tuninger, S Levander. Large variations of plasma levels during maintenance treatment with depot neuroleptics. The British journal of psychiatry : the journal of mental science. 1996 Nov; 169(5):618-21. doi: 10.1192/bjp.169.5.618. [PMID: 8932892]
  • M Lazzarin, F Benati, V Cesario. [Rhabdomyolysis and acute renal failure caused by haloperidol-decanoate (neuroleptic malignant syndrome)]. Recenti progressi in medicina. 1996 Sep; 87(9):422-4. doi: NULL. [PMID: 9053957]
  • F C Wei, M W Jann, H N Lin, C Piao-Chien, W H Chang. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. The Journal of clinical psychiatry. 1996 Jul; 57(7):298-302. doi: NULL. [PMID: 8666571]
  • A Viala, N Aymard, A Leyris, F Caroli. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate]. Therapie. 1996 Jan; 51(1):19-25. doi: NULL. [PMID: 8762216]
  • M W Jann, F C Wei, H N Lin, C Piao-Chien, W H Chang. Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate. Progress in neuro-psychopharmacology & biological psychiatry. 1996 Jan; 20(1):73-86. doi: 10.1016/0278-5846(95)00293-6. [PMID: 8861178]
  • N Aymard, A Viala, I Stein, F Caroli. Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid. Progress in neuro-psychopharmacology & biological psychiatry. 1995 Nov; 19(7):1119-35. doi: 10.1016/0278-5846(95)00230-8. [PMID: 8787036]
  • J M Rider, T F Mauger, J P Jameson, D D Notman. Water handling in patients receiving haloperidol decanoate. The Annals of pharmacotherapy. 1995 Jul; 29(7-8):663-6. doi: 10.1177/106002809502907-801. [PMID: 8520076]
  • S Nyberg, L Farde, C Halldin, M L Dahl, L Bertilsson. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. The American journal of psychiatry. 1995 Feb; 152(2):173-8. doi: 10.1176/ajp.152.2.173. [PMID: 7840348]
  • D C Goff, K K Midha, O Sarid-Segal, J W Hubbard, E Amico. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology. 1995 Feb; 117(4):417-23. doi: 10.1007/bf02246213. [PMID: 7604142]
  • G Pupeschi, C Agenet, J C Levron, M H Barges-Bertocchio. Do enzyme inducers modify haloperidol decanoate rate of release?. Progress in neuro-psychopharmacology & biological psychiatry. 1994 Dec; 18(8):1323-32. doi: 10.1016/0278-5846(94)90096-5. [PMID: 7863019]
  • S J Dencker, I Giös, E Mårtensson, T Nordén, G Nyberg, R Persson, G Roman, O Stockman, K O Svärd. A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology. 1994 Feb; 114(1):24-30. doi: 10.1007/bf02245440. [PMID: 7846204]
  • P Monteleone, A Piccolo, M Martino, M Maj. Seasonal variation in the dexamethasone suppression test: a longitudinal study in chronic schizophrenics and in healthy subjects. Neuropsychobiology. 1994; 30(2-3):61-5. doi: 10.1159/000119137. [PMID: 7800165]
  • L Ereshefsky, G Toney, S R Saklad, C Anderson, D Seidel. A loading-dose strategy for converting from oral to depot haloperidol. Hospital & community psychiatry. 1993 Dec; 44(12):1155-61. doi: 10.1176/ps.44.12.1155. [PMID: 7907570]
  • S Baruah, R Waziri, A Sherman. Neuroleptic effects on serine and glycine metabolism. Biological psychiatry. 1993 Oct; 34(8):544-50. doi: 10.1016/0006-3223(93)90197-l. [PMID: 7903868]
  • W H Chang, S K Lin, D J Juang, L C Chen, C H Yang, H Y Lane, M W Jann. Effects of haloperidol decanoate on plasma homovanillic acid in chronic schizophrenic patients. Biological psychiatry. 1993 Apr; 33(7):557-9. doi: 10.1016/0006-3223(93)90014-5. [PMID: 8513043]
  • W H Chang, S K Lin, D J Juang, L C Chen, C H Yang, W H Hu, C P Chien, Y W Lam, M W Jann. Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal. Schizophrenia research. 1993 Mar; 9(1):35-40. doi: 10.1016/0920-9964(93)90007-6. [PMID: 8461270]
  • W H Chang, S K Lin, D J Juang, L C Chen, C H Yang, W H Hu, C P Chien, Y F Lam, M W Jann. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics. Progress in neuro-psychopharmacology & biological psychiatry. 1993 Jan; 17(1):105-12. doi: NULL. [PMID: 8416597]
  • M W Dysken, S W Kim, G Vatassery, S B Johnson, S Skare, L Holden, L Thomsyck. Haloperidol decanoate pharmacokinetics in red blood cells and plasma. Journal of clinical psychopharmacology. 1992 Apr; 12(2):128-32. doi: NULL. [PMID: 1573034]
  • Y Oh-e, H Miyazaki, Y Matsunaga, M Hashimoto. Pharmacokinetics of haloperidol decanoate in rats. Journal of pharmacobio-dynamics. 1991 Nov; 14(11):615-22. doi: 10.1248/bpb1978.14.615. [PMID: 1687285]
  • K Eklund, A Forsman. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo. Clinical neuropharmacology. 1991; 14 Suppl 2(?):S7-12; discussion S12. doi: NULL. [PMID: 1684310]
  • C Cahard, P P Rop, T Conquy, A Viala. High-performance liquid chromatographic analysis of haloperidol and hydroxyhaloperidol in plasma after solid-phase extraction. Journal of chromatography. 1990 Oct; 532(1):193-202. doi: 10.1016/s0378-4347(00)83769-x. [PMID: 2079535]
  • D H Wiles, R G McCreadie, A Whitehead. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. Psychopharmacology. 1990; 101(2):274-81. doi: 10.1007/bf02244140. [PMID: 2349370]
  • C A Altamura, F Colacurcio, M C Mauri, A R Moro, F De Novellis. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels. Progress in neuro-psychopharmacology & biological psychiatry. 1990; 14(1):25-35. doi: 10.1016/0278-5846(90)90061-k. [PMID: 1967847]
  • L Ereshefsky, S R Saklad, T Tran-Johnson, G Toney, R C Lyman, C M Davis. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. Psychopharmacology bulletin. 1990; 26(1):108-14. doi: NULL. [PMID: 2371365]
  • J S Froemming, Y W Lam, M W Jann, C M Davis. Pharmacokinetics of haloperidol. Clinical pharmacokinetics. 1989 Dec; 17(6):396-423. doi: 10.2165/00003088-198917060-00004. [PMID: 2689040]
  • G Chouinard, L Annable, W Campbell. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Journal of clinical psychopharmacology. 1989 Aug; 9(4):247-53. doi: . [PMID: 2570086]
  • E Rueda-Vasquez. Outcome of treatment with haloperidol decanoate in a patient with schizophrenia, chronic undifferentiated type, and end stage renal disease. Military medicine. 1988 Nov; 153(11):595. doi: NULL. [PMID: 2907928]
  • J P McKane, A D Robinson, D H Wiles, R G McCreadie, G S Stirling. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. The British journal of psychiatry : the journal of mental science. 1987 Sep; 151(?):333-6. doi: 10.1192/bjp.151.3.333. [PMID: 3322467]
  • Y Matsunaga, K Nambu, Y Oh-e, H Miyazaki, M Hashimoto. Absorption of intramuscularly administered [14C]haloperidol decanoate in rats. European journal of drug metabolism and pharmacokinetics. 1987 Jul; 12(3):175-81. doi: 10.1007/bf03189894. [PMID: 3436339]
  • Y Oh-e, H Miyazaki, Y Matsunaga, K Nambu, N Kobayashi, M Hashimoto. Hydrolysis of haloperidol decanoate in vitro by cultured cells. European journal of drug metabolism and pharmacokinetics. 1987 Jul; 12(3):183-8. doi: 10.1007/bf03189895. [PMID: 3436340]
  • K Nambu, H Miyazaki, Y Nakanishi, Y Oh-e, Y Matsunaga, M Hashimoto. Enzymatic hydrolysis of haloperidol decanoate and its inhibition by proteins. Biochemical pharmacology. 1987 May; 36(10):1715-22. doi: 10.1016/0006-2952(87)90058-x. [PMID: 3593395]
  • J C Levron, R Ropert. [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. L'Encephale. 1987 Mar; 13(2):83-7. doi: . [PMID: 2885172]
  • R Beresford, A Ward. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs. 1987 Jan; 33(1):31-49. doi: 10.2165/00003495-198733010-00002. [PMID: 3545764]
  • Y G Gelders. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate. International clinical psychopharmacology. 1986 Jul; 1 Suppl 1(?):1-11. doi: NULL. [PMID: 3559159]
  • H De Cuyper, J Bollen, H M van Praag, D Verstraeten. Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. The British journal of psychiatry : the journal of mental science. 1986 May; 148(?):560-6. doi: 10.1192/bjp.148.5.560. [PMID: 2877701]
  • Y Matsunaga, K Nambu, Y Oh-e, H Miyazaki, M Hashimoto. Excretion and metabolism of intramuscularly administered [14C]-haloperidol decanoate in rats. Arzneimittel-Forschung. 1986 Mar; 36(3):453-6. doi: NULL. [PMID: 3707664]
  • N P Vasavan Nair, B Suranyi-Cadotte, G Schwartz, J X Thavundayil, A Achim, E Lizondo, R Nayak. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. Journal of clinical psychopharmacology. 1986 Feb; 6(1 Suppl):30S-37S. doi: 10.1097/00004714-198602001-00006. [PMID: 3514689]
  • M W Jann, L Ereshefsky, S R Saklad. Clinical pharmacokinetics of the depot antipsychotics. Clinical pharmacokinetics. 1985 Jul; 10(4):315-33. doi: 10.2165/00003088-198510040-00003. [PMID: 2864156]
  • W Kissling, H J Möller, K Walter, B Wittmann, R Krueger, D Trenk. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention. Pharmacopsychiatry. 1985 May; 18(3):240-5. doi: 10.1055/s-2007-1017373. [PMID: 4011672]
  • G Meco, M Casacchia, M Attenni, A Iafrate, F Castellana, U Ecari. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects. Acta psychiatrica Belgica. 1983 Jan; 83(1):57-68. doi: NULL. [PMID: 6613612]
  • M Viukari, H Salo, U Lamminsivu, A Gordin. Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients. Acta psychiatrica Scandinavica. 1982 Apr; 65(4):301-8. doi: 10.1111/j.1600-0447.1982.tb00850.x. [PMID: 7080851]
  • A J Reyntigens, J J Heykants, R J Woestenborghs, Y G Gelders, T J Aerts. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up. International pharmacopsychiatry. 1982; 17(4):238-46. doi: 10.1159/000468580. [PMID: 7185768]